Report Code : A04249
According to Onkar Sumant, Manager, “Increase in prevalence of disease such as stroke and hypertension, majorly drives the market growth. Moreover, the need to create awareness about optimal treatment of aSAH further drives market growth.”
Onkar Sumant - Manager
Life Sciences at Allied Market Research
According to a new report published by Allied Market Research, titled, “Aneurysmal Subarachnoid Hemorrhage Drugs Market," The aneurysmal subarachnoid hemorrhage drugs market size was valued at $323.51 million in 2020, and is estimated to reach $456.31 million by 2030, growing at a CAGR of 3.6% from 2021 to 2030.
Aneurysmal subarachnoid hemorrhage (aSAH) is a type of stroke, which is caused by bleeding in subarachnoid space of the brain. Major reasons for aneurysmal subarachnoid hemorrhage include brain aneurysm, arteriovenous malformation, or head injury.
Rise in the cases of berry aneurysm, high blood pressure, drug use, and rise in geriatric population are the major factors that contribute to the growth of the market. Moreover, increase in prevalence of hypertension and stroke boost the market growth. ASAH is prevalent among higher age group mostly in women. The population is predicted to encounter numerous severe disorders with increase in age, which include stroke and cerebral aneurysms. Hence, surge in geriatric population is expected to fuel the growth of aSAH Drugs Market size across globe throughout the forecast period.
Medication or drugs used during treatment of aSAH prevent blockages in the brain; however, they have certain side effects. For instance, nimodipine is a key drug that reduces chances of secondary cerebral ischemia, which is one of the major complications of subarachnoid hemorrhage. However, this drug has certain side effects, which include flushing, feeling sick, increasing heart rate, headaches, and rash. This factor is expected to impede growth of the aSAH market.
Subarachnoid hemorrhage (SAH) is a type of stroke, which is caused by a ruptured aneurysm, arteriovenous malformation (AVM), or head injury. One-third of the total patients survive with good recovery, another one-third survive with a disability, and remaining one-third die before receiving medical attention of total patient base of subarachnoid hemorrhage. Despite widespread availability of modern diagnostic and treatment modalities, many patients fail to reach specialized centers until hours or days following hemorrhage. Thus, there is a need to create general awareness among primary and community physicians about optimal diagnostic and therapeutic maneuvers in patients with suspected SAH. Campaigns that include brain aneurysmal awareness month are expected to create lucrative opportunities for the growth of the aSAH drugs market.
The aSAH drugs market share in this report is studied on the basis of drug class and region. On the basis of drug class, the market is classified into opioid analgesic, calcium channel blocker, anticonvulsants, stool softeners, osmotic agents/diuretics, and other drugs. The calcium channel blocker segment dominated the market and is expected to continue this trend during the forecast period, owing to increasing prevalence rate of cardiovascular diseases, changing lifestyle and hypertension. Rising assistance to people with anxiety disorders or bipolar disorder is also expected to help in the growth of the aneurysmal subarachnoid hemorrhage drugs market. In addition, increase patient awareness level, availability of the treatment options and vulnerable geriatric population are some of the influencing factors propelling the growth of the calcium channel blocker aSAH drugs market.
Region wise, North America dominated the market in 2020, owing to favorable healthcare infrastructure, which facilitated access to advanced aSAH drugs. In addition,, government initiatives, including the Precision Medicine and Affordable Care Act along with well-planned reimbursement policies contributed to the market growth in North America. Moreover, surge in awareness among people and high purchasing parity resulted in increase in demand for these devices. However, Asia-Pacific aSAH Drugs Industry is expected to witness considerable market growth during the forecast period, due to rise in government support to enhance healthcare infrastructure. Economic developments in countries, including India and China with higher disposable incomes fuel the demand for the products.
Talk to David (Europe)
Talk to Sona Padman (Americas)
5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91 2066346060
Fax: +1(855) 550-5975
Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at
media@alliedmarketresearch.com
Aneurysmal Subarachnoid Hemorrhage Drugs Market by Drug Class (Opioid Analgesic, Calcium Channel Blocker, Anticonvulsant, Stool Softener, Osmotic Agents/Diuretics, Other Drugs): Global Opportunity Analysis and Industry Forecast, 2020-2030
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Buy Full Version
"Aneurysmal Subarachnoid Hemorrhage Drugs Market"
Purchase Enquiry
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save the time of readers